Figure 1
From: FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer
Loss of FADD in ex vivo NSCLC can result from FADD release. (A–C) Fas-associated death domain protein immunohistochemistry analysis of NT (A) and T tissues (B and C). T0, neg; T1, +; T2, ++; T3, +++. A, alveolar; B, bronchial; EC, epithelial cells; Cy, cytoplasm; Nu, nucleus; T, tumour. (D) According to the patients' cancer stage, in vitro T biopsies' FADD release (extracellular FADD) determined by ELISA and ex vivo tumour cells' intracellular FADD expression determined by IHC were inversely correlated (n=24 patients, all from the Hôtel-Dieu). Data represented mean ±s.e.m. Intracellular FADD expression concerns tumour cells only (not normal epithelial cells). Stage I, II, III: n=5, 6, and 13, respectively.
